Home > Resources > Videos > Biggest B2B Marketing Challenges That We See Everyday as an Agency

Biggest B2B Marketing Challenges That We See Everyday as an Agency

One of the amazing blessings of getting to work at an agency is we get to see over 50 different companies and the challenges that they face. In today’s video, we’re going to talk about the biggest B2B marketing challenges that we see every day as an agency.

Spotlight

Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia’s global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing.

OTHER VIDEOS

Controlling exothermic reactions with AVA Lab Control Software

video | March 30, 2023

AVA Lab Control Software allows you to automate your chemistry by remotely controlling the devices connected to your jacketed lab reactor with full process data logging....

Watch Now

Processing For Modelling Hydrogen Atoms In Protein Structures

video | March 22, 2023

Neutron Crystallography Data Collection and Processing for Modelling Hydrogen Atoms in Protein Structures....

Watch Now

Phosphoproteomic Strategy for Profiling Osmotic Stress Signaling

video | March 17, 2023

Presented here is a phosphoproteomic approach, namely stop and go extraction tip based phosphoproteomic, which provides high-throughput and deep coverage of Arabidopsis phosphoproteome. This approach delineates the overview of osmotic stress signaling in Arabidopsis....

Watch Now

In-cell Fast Photochemical Oxidation of Proteins

video | March 14, 2023

Characterizing Cellular Proteins with In-cell Fast Photochemical Oxidation of Proteins - a 2 minute Preview of the Experimental Protocol...

Watch Now

Controlling exothermic reactions with AVA Lab Control Software

video | March 30, 2023

AVA Lab Control Software allows you to automate your chemistry by remotely controlling the devices connected to your jacketed lab reactor with full process data logging....

Watch Now

Processing For Modelling Hydrogen Atoms In Protein Structures

video | March 22, 2023

Neutron Crystallography Data Collection and Processing for Modelling Hydrogen Atoms in Protein Structures....

Watch Now

Phosphoproteomic Strategy for Profiling Osmotic Stress Signaling

video | March 17, 2023

Presented here is a phosphoproteomic approach, namely stop and go extraction tip based phosphoproteomic, which provides high-throughput and deep coverage of Arabidopsis phosphoproteome. This approach delineates the overview of osmotic stress signaling in Arabidopsis....

Watch Now

In-cell Fast Photochemical Oxidation of Proteins

video | March 14, 2023

Characterizing Cellular Proteins with In-cell Fast Photochemical Oxidation of Proteins - a 2 minute Preview of the Experimental Protocol...

Watch Now
MORE VIDEOS

Spotlight

Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia’s global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing.

Events